$3995 | Single User
$7990 | Site License
$11985 | Enterprise License

EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024
[Published by Global Data]

Published by Global Data: 01 Jan 2016 | 17998 | In Stock
Related Topics: Lymphoma

Introduction

EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024

Summary

Non-Hodgkin’s Lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the body’s immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body’s inability to fight infections and other diseases. NHL is characterized into three types - B-cell, T-cell, and natural killer lymphocyte lymphomas. This epidemiological analysis focuses specifically on four subtypes of B-cell NHL: follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma. NHL is more common in men than in women, in white men and women compared with black men and women, and the incidence exponentially increases with age.

GlobalData epidemiologists forecast an increase in the incident cases of the four B-cell NHL in the 7MM, from 104,854 incident cases in 2014 to 129,179 incident cases in 2024, with an annual growth rate (AGR) of 2.32%. Throughout the forecast period, the US will have the highest number of incident cases of B-cell NHL, as well as 36% growth during the forecast period, ending with 57,724 incident cases in 2024. Additionally, each of the 7MM will see an increase in incident cases over the 10-year forecast period.

For this analysis, GlobalData epidemiologists utilized peer-reviewed journals and country-specific disease databases to construct the 10-year epidemiological forecast for the incident cases of follicular lymphoma, marginal zone lymphoma, DLBCL, and mantle cell lymphoma in the 7MM. A major strength of GlobalData’s epidemiological analysis is the exclusive use of country-specific sources, allowing for a meaningful comparison of the epidemiological characteristics of B-cell NHL in the 7MM. In addition, this forecast provides detailed segmentation of the B-cell NHL for each country by age, sex, and B-cell NHL subtype, thereby providing a comprehensive view of B-cell NHL in the seven markets. Furthermore, GlobalData epidemiologists constructed and analyzed each B-cell NHL subtype individually, which facilitated an in-depth understanding of B-cell NHL in the 7MM.

Scope

- The Non-Hodgkin’s Lymphoma (NHL) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for NHL in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the incident cases of NHL segmented by sex, age (in five-year increments beginning at 30 years and ending at =85 years), and subtypes in these markets.

- The NHL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The NHL EpiCast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global NHL market.

- Quantify patient populations in the global NHL market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for NHL therapeutics in each of the markets covered.

Table of Contents
for EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024 [Published by Global Data]

  • 1 Table of Contents

    1 Table of Contents 3

    1.1 List of Tables 5

    1.2 List of Figures 6

    2 Introduction 7

    2.1 Catalyst 7

    2.2 Related Reports 8

    2.3 Upcoming Reports 8

    3 Epidemiology 9

    3.1 Disease Background 9

    3.2 Risk Factors and Comorbidities 9

    3.3 Global Trends 12

    3.3.1 US 12

    3.3.2 5EU 13

    3.3.3 Japan 16

    3.4 Forecast Methodology 16

    3.4.1 Sources Used 19

    3.4.2 Sources Not Used 22

    3.4.3 Forecast Assumptions and Methods 23

    3.5 Epidemiological Forecast for B-Cell NHL (2014-2024) 27

    3.5.1 Follicular Lymphoma 27

    3.5.2 Marginal Zone Lymphoma 35

    3.5.3 DLBCL 42

    3.5.4 Mantle Cell Lymphoma 49

    3.6 Discussion 56

    3.6.1 Epidemiological Forecast Insight 56

    3.6.2 Limitations of the Analysis 56

    3.6.3 Strengths of the Analysis 57

    4 Appendix 58

    4.1 Bibliography 58

    4.2 About the Authors 62

    4.2.1 Epidemiologists 62

    4.2.2 Reviewers 63

    4.2.3 Global Director of Therapy Analysis and Epidemiology 64

    4.2.4 Global Head of Healthcare 64

    4.3 About GlobalData 65

    4.4 About EpiCast 65

    4.5 Disclaimer 66

List Of Tables
in EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024 [Published by Global Data]

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for NHL 11

Table 2: US, Age- and Sex-Specific Incidence of B-Cell NHL during 2001-2010 13

Table 3: 7MM, Sources of B-Cell NHL Incidence Data 18

Table 4: 7MM, Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024 28

Table 5: 7MM, Age-Specific Incident Cases of Follicular Lymphoma, Both Sexes, N (Row %), 2014 30

Table 6: 7MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, N (Row %), 2014 32

Table 7: 7MM, Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024 35

Table 8: 7MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Both Sexes, N (Row %), 2014 37

Table 9: 7MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, N (Row %), 2014 39

Table 10: 7MM, Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024 42

Table 11: 7MM, Age-Specific Incident Cases of DLBCL, Both Sexes, N (Row %), 2014 44

Table 12: 7MM, Sex-Specific Incident Cases of DLBCL, Ages ≥30 Years, N (Row %), 2014 46

Table 13: 7MM, Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024 49

Table 14: 7MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N (Row %), 2014 51

Table 15: 7MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, N (Row %), 2014 53

List Of Figures, Charts and Diagrams
in EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024 [Published by Global Data]

1.2 List of Figures

Figure 1: 7MM, Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014-2024 28

Figure 2: 7MM, Age-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014 31

Figure 3: 7MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, N, 2014 33

Figure 4: 7MM, Age-Standardized Incidence of Follicular Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014 34

Figure 5: 7MM, Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014-2024 36

Figure 6: 7MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014 38

Figure 7: 7MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, N, 2014 40

Figure 8: 7MM, Age-Standardized Incidence of Marginal Zone Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014 41

Figure 9: 7MM, Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, 2014-2024 43

Figure 10: 7MM, Age-Specific Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, 2014 45

Figure 11: 7MM, Sex-Specific Incident Cases of DLBCL, Ages ≥30 Years, N, 2014 47

Figure 12: 7MM, Age-Standardized Incidence of DLBCL (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014 48

Figure 13: 7MM, Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014-2024 50

Figure 14: 7MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N, 2014 52

Figure 15: 7MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, N, 2014 54

Figure 16: 7MM, Age-Standardized Incidence of Mantle Cell Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014 55

Additional Details

Publisher

Global Data

Publisher Information

Reference

17998 | GDHCER113-15

Number of Pages

67

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024
EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024SummaryPulmonary Arte...
01 Jan 2016 by Global Data USD $3,995 More Info
EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024
EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024SummarySmall Cell Lung Cancer ...
01 Jan 2016 by Global Data USD $3,995 More Info
EpiCast Report: Vasculitis - Epidemiology Forecast to 2024
EpiCast Report: Vasculitis - Epidemiology Forecast to 2024SummaryVasculitis is a group of heterogene...
01 Jan 2016 by Global Data USD $3,995 More Info
EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024
EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024SummaryThe Hepatitis B Virus (HBV...
24 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024
EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024SummaryRSV is a...
23 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024
EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024SummarySjögren’s syndrome (SS) is ...
09 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024
EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024SummaryHuntington’s disease (HD)...
09 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024
EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024SummarySystemic scle...
09 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023SummaryC...
01 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024SummaryPrimary brain cancer is defined a...
01 Dec 2015 by Global Data USD $3,995 More Info

This report is published by Global Data

Download Free Report Summary PDF

EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Bizwit Research and Consulting
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)
  • VPA Research